Physician profile
Sumit Talwar
NPI 1679752547
$6,606.00
in general payments reported to CMS, 2019-2025
51 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $753 · 2021: $556 · 2022: $274 · 2023: $379 · 2024: $1,613 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,485 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,484.88 |
| Education | $200.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $737.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $709.50 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Celgene Corporation | $427.17 | 2019-2025 | Reblozyl |
| Genentech USA, INC. | $405.55 | 2019-2025 | Alecensa, Tecentriq |
| Daiichi Sankyo INC. | $376.95 | 2020-2025 | Injectafer, Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $330.91 | 2019-2025 | Lynparza, Tagrisso |
| Pfizer INC. | $319.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $256.54 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $247.26 | 2019-2025 | |
| Janssen Biotech, INC. | $226.59 | 2019-2024 | Erleada, Tecvayli |
| Glaxosmithkline, LLC. | $214.91 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Lilly USA, LLC | $209.42 | 2019-2025 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $188.48 | 2020-2025 | Padcev, Vyloy, Xospata |
| Gilead Sciences, INC. | $153.01 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $122.24 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.